Summary
Abbott Laboratories (ABT) filed an 8-K on January 25, 2017, to report on events impacting its financial reporting following the completion of its acquisition of St. Jude Medical, Inc. on January 4, 2017. This filing is significant as it outlines the new segment structure for Abbott's cardiovascular and neuromodulation (ACN) business, which now incorporates St. Jude Medical's operations. Investors should note the reclassification of products into specific categories within ACN, which will be crucial for understanding future sales performance and segment growth. The company has provided details on how its ACN sales will be reported, divided into "Rhythm Management and Heart Failure," "Cardiovascular and Structural Heart," and "Neuromodulation." The filing also directs investors to Exhibit 99.1 for comparable revenue data by product category for the full year 2016 and quarterly periods within 2016. This exhibit is essential for investors to establish a baseline and assess the initial performance of the combined entity in the upcoming reporting periods.
Key Highlights
- 1Abbott Laboratories completed the acquisition of St. Jude Medical, Inc. on January 4, 2017.
- 2The filing details the revised reporting structure for Abbott's Cardiovascular and Neuromodulation (ACN) business.
- 3The ACN business will now include former St. Jude Medical product lines.
- 4New reporting categories within ACN are: Rhythm Management and Heart Failure, Cardiovascular and Structural Heart, and Neuromodulation.
- 5Exhibit 99.1 provides comparable revenue data for these product categories for 2016.
- 6This information is crucial for understanding the financial performance of the integrated St. Jude Medical business starting in Q1 2017.